Skip to content

Advertisement

  • Oral presentation
  • Open Access

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Trials201516 (Suppl 2) :O4

https://doi.org/10.1186/1745-6215-16-S2-O4

  • Published:

Keywords

  • Public Health
  • Prostate Cancer
  • Systematic Review
  • Empirical Evidence
  • Randomise Control Trial

Background

Systematic reviews of RCTs are recognised as the optimal way to resolve or confirm uncertainty about the effects of interventions. They can provide the rationale for the design of a new trial, inform the conduct of an ongoing trial, and help place trial results in the context of those from related trials. However, empirical evidence suggests that few trials use systematic reviews in these ways.

Methods

To describe how MRC CTU has actively used evidence synthesis to inform the design, conduct and analysis of its cancer trials.

Results

Initially, we used systematic reviews/searches to aid the interpretation and reporting of the results of MRC CTU cancer trials in light of other evidence. Subsequently, we have synthesised external evidence, to provide the rationale for new trials or protocol modifications for ongoing trials, for example, in response to new predictive biomarkers emerging during their conduct. Currently, systematic reviews are informing adaptations to our ongoing, multi-arm, multi-stage cancer trials, for example, to select the most appropriate therapies for new arms. We also plan to use prospective, retrospective and network meta-analyses of aggregate data and IPD, to tailor evidence synthesis to the specific needs of our ongoing trials, in the context of other trial evidence. We will present examples of evidence synthesis informing lung, colorectal, breast, upper GI and prostate cancer trials.

Conclusions

Evidence synthesis has a key role to play at all stages of trials, particularly those conducted in the long term. We discuss the implications for those conducting such trials.

Authors’ Affiliations

(1)
MRC Clinical Trials Unit at UCL, London, UK

Copyright

© Tierney et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement